Updates on Human Genome Sciences (NASDAQ: HGSI) ratings and price targets.
Human Genome Sciences (NASDAQ: HGSI) had its “Neutral” rating reiterated by Goldman Sachs (NYSE: GS).
Citigroup (NYSE: C) lowered their price target on Human Genome Sciences to $8.00.
Barclays Capital (NYSE: BCS) initiated coverage on Human Genome Sciences. They placed an “Equal Weight” rating and a price target of $8.00 on the company.
Stifel Nicolaus lowered their price target on Human Genome Sciences (NASDAQ: HGSI) from $17.00 to $15.00. They have a “Buy” rating on the company.
Summer Street has a price target of $23.00 on Human Genome Sciences.
No comments:
Post a Comment